Lifeline Scientific, Inc Trading update (7712I)
02 9월 2016 - 3:00PM
UK Regulatory
TIDMLSIC
RNS Number : 7712I
Lifeline Scientific, Inc
02 September 2016
2 September 2016
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Trading update
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, announces a trading update for the six months ended 30
June 2016.
The prospects for Lifeline Scientific continue to remain solid
for 2016, with trading in the first half significantly ahead of the
same period last year. The Company saw strong growth across its
North American, South American and European markets and expects to
report revenues for transplantation products and revenues for the
six month period up 21.1% to US$18.2m (H1 2015: US$15.0m), with
sales of proprietary single-use consumables up 24.7% to US$10.6m
(H1 2015: US$8.5m).
Operating Profit in the first half showed considerable growth,
with the Company expecting to report income from operations of
US$2.0m, significantly up from the US$0.1m recorded in the same
period last year. Profit Before Tax is expected to be US$2.0m (H1
2015: US$0.1m).
The Company's cash position remains strong with US$1.6m of cash
generated from operations in the first half (H1 2015: US$1.0m),
which resulted in cash balances as of 30 June 2016 of US$7.5m (31
December 2015: US$6.9m).
Lifeline will announce its interim results for the six months
ended 30 June 2016 on Monday 26 September 2016.
David Kravitz, CEO of Lifeline Scientific, commented: "We made
solid progress during the first half of 2016 and look forward to
reporting our Half-Year Results later this month."
For further information:
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886
(NOMAD and Broker) 2500
Freddy Crossley / Duncan Montieth
(Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780
or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541
893
Lianne Cawthorne Mob: +44 (0)7584 391
303
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of donor kidneys. Employed by surgeons in
over 218 leading transplant programmes in 32 countries, LifePorts
have successfully preserved more than 70,000 kidneys indicated for
clinical transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and international
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine perfusion, and has been developed in
consultation with clinical and research teams specialising in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSSSSDEFMSEFU
(END) Dow Jones Newswires
September 02, 2016 02:00 ET (06:00 GMT)
Lifeline Sci (LSE:LSIC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Lifeline Sci (LSE:LSIC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
